{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:20:46Z","timestamp":1783164046741,"version":"3.54.6"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11864-025-01363-z","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:17:54Z","timestamp":1761556674000},"page":"1047-1060","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy-associated Cardiotoxicity: a Comprehensive Review of Checkpoint inhibitors, monoclonal, cellular, and cytokine-based Treatments"],"prefix":"10.1007","volume":"26","author":[{"given":"Kalliopi","family":"Keramida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora-Christina","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athos","family":"Antoniades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"1","key":"1363_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01056-8","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1363_CR2","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/ejhf.3340","volume":"26","author":"CG Tocchetti","year":"2024","unstructured":"Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L, et al. Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the heart failure association (HFA) of the ESC and the ESC council of cardio-oncology. Eur J Heart Fail. 2024;26(10):2055\u201376.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1363_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-27960-2","volume":"13","author":"M Conroy","year":"2022","unstructured":"Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun. 2022;13(1):392.","journal-title":"Nat Commun"},{"issue":"23","key":"1363_CR4","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1161\/CIRCULATIONAHA.115.010484","volume":"132","author":"AM Bellinger","year":"2015","unstructured":"Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, et al. Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation. 2015;132(23):2248\u201358.","journal-title":"Circulation"},{"key":"1363_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003594","author":"S Boughdad","year":"2021","unstructured":"Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, et al. (68)Ga-DOTATOC PET\/CT to detect immune checkpoint inhibitor-related myocarditis. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-003594.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1363_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111611","volume":"41","author":"T Won","year":"2022","unstructured":"Won T, Kalinoski HM, Wood MK, Hughes DM, Jaime CM, Delgado P, et al. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. 2022;41(6):111611.","journal-title":"Cell Rep"},{"issue":"3","key":"1363_CR7","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","volume":"11","author":"SC Wei","year":"2021","unstructured":"Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever EM, Wescott EC, et al. A genetic mouse model recapitulates immune checkpoint Inhibitor-Associated myocarditis and supports a Mechanism-Based therapeutic intervention. Cancer Discov. 2021;11(3):614\u201325.","journal-title":"Cancer Discov"},{"issue":"669","key":"1363_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo1981","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, et al. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med. 2022;14(669):eabo1981.","journal-title":"Sci Transl Med"},{"issue":"4","key":"1363_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","volume":"43","author":"L Michel","year":"2022","unstructured":"Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J. 2022;43(4):316\u201329.","journal-title":"Eur Heart J"},{"issue":"4","key":"1363_CR10","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jtho.2017.12.002","volume":"13","author":"S Du","year":"2018","unstructured":"Du S, Zhou L, Alexander GS, Park K, Yang L, Wang N, et al. PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J Thorac Oncol. 2018;13(4):510\u201320.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1363_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541\u20137.","journal-title":"Immunity"},{"issue":"2","key":"1363_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141\u201351.","journal-title":"Immunity"},{"issue":"5502","key":"1363_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319\u201322.","journal-title":"Science"},{"issue":"10","key":"1363_CR14","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 2012;188(10):4876\u201384.","journal-title":"J Immunol"},{"issue":"18","key":"1363_CR15","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"issue":"5","key":"1363_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.acvd.2022.03.003","volume":"115","author":"JR Power","year":"2022","unstructured":"Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek SS, Asnani A, et al. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. Arch Cardiovasc Dis. 2022;115(5):315\u201330.","journal-title":"Arch Cardiovasc Dis"},{"issue":"10124","key":"1363_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet (London England). 2018;391(10124):933.","journal-title":"Lancet (London England)"},{"issue":"7937","key":"1363_CR18","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, et al. T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature. 2022;611(7937):818\u201326.","journal-title":"Nature"},{"issue":"5","key":"1363_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/cvr\/cvz025","volume":"115","author":"N Grabie","year":"2019","unstructured":"Grabie N, Lichtman AH, Padera R. T cell checkpoint regulators in the heart. Cardiovascular Res. 2019;115(5):869\u201377.","journal-title":"Cardiovascular Res"},{"issue":"7","key":"1363_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02778-2","volume":"11","author":"W Xia","year":"2020","unstructured":"Xia W, Zou C, Chen H, Xie C, Hou M. Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a\/Kruppel-like factor 4 signaling. Cell Death Dis. 2020;11(7):575.","journal-title":"Cell Death Dis"},{"issue":"41","key":"1363_CR21","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"24","key":"1363_CR22","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377\u20139.","journal-title":"N Engl J Med"},{"key":"1363_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004699","author":"LS Nguyen","year":"2022","unstructured":"Nguyen LS, Bretagne M, Arrondeau J, Zahr N, Ederhy S, Abbar B, Pinna B, Allenbach Y, Mira JP, Moslehi J, Rosenzwajg M, Salem JE. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J Immunother Cancer. 2022;10(4):e004699.\u00a0https:\/\/doi.org\/10.1136\/jitc-2022-004699","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1363_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.acvd.2024.12.005","volume":"118","author":"JE Salem","year":"2025","unstructured":"Salem JE, Ederhy S, Belin L, Zahr N, Tubach F, Procureur A, et al. Abatacept dose-finding phase II trial for immune checkpoint inhibitors myocarditis (ACHLYS) trial design. Arch Cardiovasc Dis. 2025;118(2):106\u201315.","journal-title":"Arch Cardiovasc Dis"},{"issue":"18","key":"1363_CR25","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","volume":"116","author":"N Grabie","year":"2007","unstructured":"Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ, et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8\u2009+\u2009T-cell mediated injury in the heart. Circulation. 2007;116(18):2062\u201371.","journal-title":"Circulation"},{"issue":"4","key":"1363_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/eurheartj\/ehab584","volume":"43","author":"G Varricchi","year":"2022","unstructured":"Varricchi G, Galdiero MR, Tocchetti CG. Novel actors on the stage of cardiac dysfunction induced by anti-PD1 oncological treatments. Eur Heart J. 2022;43(4):330\u20132.","journal-title":"Eur Heart J"},{"issue":"4","key":"1363_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","volume":"2","author":"K Poels","year":"2020","unstructured":"Poels K, van Leent MMT, Boutros C, Tissot H, Roy S, Meerwaldt AE, et al. Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis. JACC CardioOncol. 2020;2(4):599\u2013610.","journal-title":"JACC CardioOncol"},{"issue":"24","key":"1363_CR28","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299\u2013311.","journal-title":"Circulation"},{"key":"1363_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007307","author":"ZD Drobni","year":"2023","unstructured":"Drobni ZD, Gongora C, Taron J, Suero-Abreu GA, Karady J, Gilman HK, et al. Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007307.","journal-title":"J Immunother Cancer"},{"key":"1363_CR30","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.thromres.2020.09.038","volume":"196","author":"C Solinas","year":"2020","unstructured":"Solinas C, Saba L, Sganzerla P, Petrelli F. Venous and arterial thromboembolic events with immune checkpoint inhibitors: a systematic review. Thromb Res. 2020;196:444\u201353.","journal-title":"Thromb Res"},{"issue":"2","key":"1363_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41569-022-00827-1","volume":"20","author":"K Josan","year":"2023","unstructured":"Josan K, Neilan TG. Immune checkpoint inhibitors: acute and chronic cardiovascular complications. Nat Rev Cardiol. 2023;20(2):73\u20134.","journal-title":"Nat Rev Cardiol"},{"key":"1363_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002916","author":"K Poels","year":"2021","unstructured":"Poels K, Neppelenbroek SIM, Kersten MJ, Antoni ML, Lutgens E, Seijkens TTP. Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002916.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1363_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaccao.2019.11.013","volume":"1","author":"KR Chitturi","year":"2019","unstructured":"Chitturi KR, Xu J, Araujo-Gutierrez R, Bhimaraj A, Guha A, Hussain I, et al. Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer. JACC CardioOncol. 2019;1(2):182\u201392.","journal-title":"JACC CardioOncol"},{"issue":"21","key":"1363_CR34","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085\u20137.","journal-title":"Circulation"},{"issue":"5","key":"1363_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100252","volume":"6","author":"P Jain","year":"2021","unstructured":"Jain P, Gutierrez Bugarin J, Guha A, Jain C, Patil N, Shen T, et al. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open. 2021;6(5):100252.","journal-title":"ESMO Open"},{"issue":"6","key":"1363_CR36","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/jcmm.12467","volume":"19","author":"L Liu","year":"2015","unstructured":"Liu L, Zheng Q, Lee J, Ma Z, Zhu Q, Wang Z. PD-1\/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation. J Cell Mol Med. 2015;19(6):1223\u201333.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"1363_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10557-021-07181-3","volume":"36","author":"Q Wu","year":"2022","unstructured":"Wu Q, Bai B, Tian C, Li D, Yu H, Song B, et al. The molecular mechanisms of cardiotoxicity induced by HER2, VEGF, and tyrosine kinase inhibitors: an updated review. Cardiovasc Drugs Ther. 2022;36(3):511\u201324.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1363_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.741451","volume":"12","author":"Z Yang","year":"2021","unstructured":"Yang Z, Wang W, Wang X, Qin Z. Cardiotoxicity of epidermal growth factor receptor 2-targeted drugs for breast cancer. Front Pharmacol. 2021;12:741451.","journal-title":"Front Pharmacol"},{"issue":"31","key":"1363_CR39","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820\u20136.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1363_CR40","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"E Tan-Chiu","year":"2005","unstructured":"Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr., Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1363_CR41","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","volume":"26","author":"EA Perez","year":"2008","unstructured":"Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231\u20138.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1363_CR42","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.2169\/internalmedicine.4144-24","volume":"64","author":"I Misumi","year":"2025","unstructured":"Misumi I, Nishimura R, Nakamura S, Sato K, Dekita M, Usuku H, et al. Delayed trastuzumab-induced cardiotoxicity leading to severe left ventricular dysfunction. Intern Med. 2025;64(12):1849\u201357.","journal-title":"Intern Med"},{"issue":"4","key":"1363_CR43","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/ejhf.1385","volume":"21","author":"K Keramida","year":"2019","unstructured":"Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA, et al. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. Eur J Heart Fail. 2019;21(4):529\u201335.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"1363_CR44","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215\u201321.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1363_CR45","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2010","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124\u201330.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1363_CR46","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","volume":"25","author":"TM Suter","year":"2007","unstructured":"Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol. 2007;25(25):3859\u201365.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1363_CR47","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med"},{"issue":"7","key":"1363_CR48","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328.","journal-title":"N Engl J Med"},{"issue":"2","key":"1363_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109\u201319.","journal-title":"N Engl J Med"},{"issue":"2","key":"1363_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"1363_CR51","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","volume":"7","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Im SA, Cardoso F, Cort\u00e9s J, Curigliano G, Musolino A, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-Positive advanced breast cancer: A phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573\u201384.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1363_CR52","first-page":"49","volume":"6","author":"VB Patil","year":"2020","unstructured":"Patil VB, Lunge SB, Doshi BR. Cardiac Side Effect Rituximab. 2020;6(1):49\u201352.","journal-title":"Cardiac Side Effect Rituximab"},{"issue":"3","key":"1363_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005946","volume":"96","author":"XM Tang","year":"2017","unstructured":"Tang XM, Chen H, Liu Y, Huang BL, Zhang XQ, Yuan JM, et al. The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients. Medicine (Baltimore). 2017;96(3):e5946.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"1363_CR54","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/bjc.2017.88","volume":"116","author":"N Gronich","year":"2017","unstructured":"Gronich N, Lavi I, Barnett-Griness O, Saliba W, Abernethy DR, Rennert G. Tyrosine kinase-targeting drugs-associated heart failure. Br J Cancer. 2017;116(10):1366\u201373.","journal-title":"Br J Cancer"},{"key":"1363_CR55","unstructured":"FDA. ERBITUX, prescribing information. [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125084s273lbl.pdf"},{"issue":"3","key":"1363_CR56","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","volume":"104","author":"DJ Lenihan","year":"2004","unstructured":"Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/S\u00e9zary syndrome. Blood. 2004;104(3):655\u20138.","journal-title":"Blood"},{"key":"1363_CR57","unstructured":"Lemtrada. (alemtuzumab) injection, for intravenous use. Prescribing Information. Genzyme Corporation Updated May 2022. [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/103948s5184lbl.pdf"},{"issue":"7","key":"1363_CR58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621\u201331.","journal-title":"N Engl J Med"},{"key":"1363_CR59","unstructured":"Elotuzumab Prescribing Information (Empliciti\u00ae. BMS) [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761035s017lbl.pdf"},{"issue":"13","key":"1363_CR60","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207\u201319.","journal-title":"N Engl J Med"},{"key":"1363_CR61","unstructured":"Daratumumab (Darzalex\u00ae). Prescribing Information. U.S. FDA label. [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761036s048lbl.pdf"},{"issue":"12","key":"1363_CR62","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med"},{"key":"1363_CR63","unstructured":"Obinutuzumab. (Gazyva\u00ae) Prescribing Information. Genentech\/Roche \u2013 U.S. FDA label. [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125486s047lbl.pdf"},{"issue":"1","key":"1363_CR64","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13058-025-02013-w","volume":"27","author":"J Han","year":"2025","unstructured":"Han J, Zhai X, Tao X, Li Y, Zhao Z, Yu Z, et al. Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database. Breast Cancer Research: BCR. 2025;27(1):54.","journal-title":"Breast Cancer Research: BCR"},{"key":"1363_CR65","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2020.08.033","volume":"323","author":"D Lobenwein","year":"2021","unstructured":"Lobenwein D, Kocher F, Dobner S, Gollmann-Tepek\u00f6yl\u00fc C, Holfeld J. Cardiotoxic mechanisms of cancer immunotherapy - a systematic review. Int J Cardiol. 2021;323:179\u201387.","journal-title":"Int J Cardiol"},{"issue":"1","key":"1363_CR66","doi-asserted-by":"publisher","first-page":"34","DOI":"10.22543\/7674.81.P3443","volume":"8","author":"I-E Popovici","year":"2021","unstructured":"Popovici I-E, Cozma A, Orasan OH, Ciulei G, Poenar AM, Buchman C, et al. Biochemical and echocardiographic markers for the early detection of cardiotoxicity under monoclonal antibodies therapy. J Mind Med Sci. 2021;8(1):34\u201343.","journal-title":"J Mind Med Sci"},{"issue":"20","key":"1363_CR67","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","volume":"43","author":"M Totzeck","year":"2022","unstructured":"Totzeck M, Michel L, Lin Y, Herrmann J, Rassaf T. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J. 2022;43(20):1928\u201340.","journal-title":"Eur Heart J"},{"key":"1363_CR68","unstructured":"National Cancer Institute. CAR T Cells: Engineering Patients\u2019 Immune Cells to Treat Their Cancers. 2024. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells"},{"issue":"1","key":"1363_CR69","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/annonc\/mdx755","volume":"29","author":"J Tang","year":"2018","unstructured":"Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2018;29(1):84\u201391.","journal-title":"Ann Oncol"},{"issue":"25","key":"1363_CR70","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019;74(25):3099\u2013108.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1363_CR71","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01068-0","volume":"23","author":"NP Patel","year":"2021","unstructured":"Patel NP, Doukas PG, Gordon LI, Akhter N. Cardiovascular toxicities of CAR T-cell therapy. Curr Oncol Rep. 2021;23(7):78.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"1363_CR72","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124\u201331.","journal-title":"Crit Care Med"},{"issue":"8","key":"1363_CR73","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","volume":"24","author":"DS Burstein","year":"2018","unstructured":"Burstein DS, Maude S, Grupp S, Griffis H, Rossano J, Lin K. Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience. Biol Blood Marrow Transplant. 2018;24(8):1590\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"303","key":"1363_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.","journal-title":"Sci Transl Med"},{"issue":"18","key":"1363_CR75","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol. 2021;78(18):1800\u201313.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"1363_CR76","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","volume":"142","author":"S Ganatra","year":"2020","unstructured":"Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, et al. Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation. 2020;142(17):1687\u201390.","journal-title":"Circulation"},{"issue":"1","key":"1363_CR77","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","volume":"2","author":"AK Ghosh","year":"2020","unstructured":"Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C. CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? JACC CardioOncol. 2020;2(1):97\u2013109.","journal-title":"JACC CardioOncol"},{"issue":"2","key":"1363_CR78","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"5","key":"1363_CR79","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","volume":"4","author":"S Ganatra","year":"2022","unstructured":"Ganatra S, Dani SS, Yang EH, Zaha VG, Nohria A. Cardiotoxicity of T-cell antineoplastic therapies: JACC: cardiooncology primer. JACC CardioOncol. 2022;4(5):616\u201323.","journal-title":"JACC CardioOncol"},{"issue":"4","key":"1363_CR80","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1363_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1553966","volume":"12","author":"E Gavriilaki","year":"2025","unstructured":"Gavriilaki E, Tzannou I, Vardi A, Tsonis I, Liga M, Gkirkas K, et al. Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece. Front Med. 2025;12:1553966.","journal-title":"Front Med"},{"key":"1363_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1597512","volume":"16","author":"J Zhang","year":"2025","unstructured":"Zhang J, Xie D, Tang M, Gong Q, Huang X, Li J, et al. Utilizing plasma exchange for severe cytokine release syndrome after CAR-T cell therapy: clinical experience and literature insights. Front Immunol. 2025;16:1597512.","journal-title":"Front Immunol"},{"issue":"8","key":"1363_CR83","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1007\/s00277-025-06511-x","volume":"104","author":"SM Stolz","year":"2025","unstructured":"Stolz SM, Musa A, Bachofner A, Bankova AK, Gourri E, Manz MG, et al. Prophylactic tocilizumab prior to infusion of CD19 CAR T-cells reduces therapy-related complications in older lymphoma patients. Ann Hematol. 2025;104(8):4149\u201355.","journal-title":"Ann Hematol"},{"issue":"7","key":"1363_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.019","volume":"29","author":"C De Philippis","year":"2023","unstructured":"De Philippis C, Mannina D, Giordano L, Costantini E, Marcheselli S, Mariotti J, et al. Impact of preemptive use of Tocilizumab on chimeric antigen receptor T cell outcomes in Non-Hodgkin lymphoma. Transplant Cell Ther. 2023;29(7):e4291\u20136.","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"1363_CR85","first-page":"e28162","volume":"14","author":"KS Hanna","year":"2022","unstructured":"Hanna KS, Kaur H, Alazzeh MS, Thandavaram A, Channar A, Purohit A, et al. Cardiotoxicity associated with chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies: A systematic review. Cureus. 2022;14(8):e28162.","journal-title":"Cureus"},{"issue":"11","key":"1363_CR86","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","volume":"128","author":"AH Baik","year":"2021","unstructured":"Baik AH, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, et al. Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ Res. 2021;128(11):1780\u2013801.","journal-title":"Circ Res"},{"issue":"18","key":"1363_CR87","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1363_CR88","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00277-018-3495-2","volume":"98","author":"SH Jung","year":"2019","unstructured":"Jung SH, Lee SR, Yang DH, Lee S, Yoon JH, Lee H, et al. Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed\/refractory acute lymphoblastic leukemia on behalf of the Korean society of hematology ALL working party. Ann Hematol. 2019;98(1):151\u20138.","journal-title":"Ann Hematol"},{"key":"1363_CR89","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008518","author":"A Sayed","year":"2024","unstructured":"Sayed A, Munir M, Ghazi SM, Ferdousi M, Krishan S, Shaaban A, Habib A, Kola-Kehinde O, Ruz P, Khan S, Sharma S, Meara A, Mahmood S, Feldman S, Yang EH, Kim J, Epperla N, Addison D. Cardiovascular toxicities associated with bispecific T-cell engager therapy. J Immunother Cancer. 2024 Feb 21;12(2):e008518. doi: 10.1136\/jitc-2023-008518. PMID: 38388168; PMCID: PMC10882360. https:\/\/doi.org\/10.1136\/jitc-2023-008518","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1363_CR90","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.hfc.2022.02.008","volume":"18","author":"AF Stein-Merlob","year":"2022","unstructured":"Stein-Merlob AF, Ganatra S, Yang EH. T-cell immunotherapy and cardiovascular disease: chimeric antigen receptor T-cell and bispecific T-cell engager therapies. Heart Fail Clin. 2022;18(3):443\u201354.","journal-title":"Heart Fail Clin"},{"issue":"2","key":"1363_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102383","volume":"9","author":"JSW Borgers","year":"2024","unstructured":"Borgers JSW, van Schijndel AW, van Thienen JV, Klobuch S, Seijkens TTP, Tobin RP, et al. Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned. ESMO Open. 2024;9(2):102383.","journal-title":"ESMO Open"},{"issue":"7","key":"1363_CR92","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105\u201316.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1363_CR93","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1080\/14740338.2017.1382472","volume":"16","author":"S Marabondo","year":"2017","unstructured":"Marabondo S, Kaufman HL. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Expert Opin Drug Saf. 2017;16(12):1347\u201357.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1363_CR94","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/CJI.0000000000000341","volume":"44","author":"MG Fradley","year":"2021","unstructured":"Fradley MG, Damrongwatanasuk R, Chandrasekhar S, Alomar M, Kip KE, Sarnaik AA. Cardiovascular toxicity and mortality associated with adoptive cell therapy and tumor-infiltrating lymphocytes for advanced stage melanoma. J Immunother. 2021;44(2):86\u20139.","journal-title":"J Immunother"},{"key":"1363_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"S Farkona","year":"2016","unstructured":"Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.","journal-title":"BMC Med"},{"key":"1363_CR96","unstructured":"BCG live intravesical (Theracys). Available from: https:\/\/www.vaccineshoppe.com\/assets\/pdf\/theracys.pdf"},{"key":"1363_CR97","unstructured":"FDA. UNITUXIN: highlights of prescribing information. Available from: https:\/\/www.fda.gov\/media\/78511\/download"},{"key":"1363_CR98","unstructured":"FDA. IMLYGIC: Highlights of prescribing information. Available from: https:\/\/www.fda.gov\/media\/94129\/download"},{"key":"1363_CR99","unstructured":"Ferring Announces Full Availability of ADSTILADRIN\u00ae (nadofaragene. firadenovec-vncg) in the U.S. Available from: https:\/\/www.businesswire.com\/news\/home\/20240116546395\/en\/Ferring-Announces-Full-Availability-of-ADSTILADRIN%C2%AE-nadofaragene-firadenovec-vncg-in-the-U.S"},{"key":"1363_CR100","doi-asserted-by":"crossref","unstructured":"Moey MYY, Jiwani RA, Takeda K, Prenshaw K, Kreeger RW, Inzerillo J, et al. Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database. ESC Heart Failure. 2021;8(4):3360-8.","DOI":"10.1002\/ehf2.13400"},{"key":"1363_CR101","doi-asserted-by":"crossref","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England J Med. 2010;363(5):411-22.","DOI":"10.1056\/NEJMoa1001294"},{"key":"1363_CR102","doi-asserted-by":"crossref","unstructured":"Geetha SD, Chavarria HD, Abdelwahed M, Kataria N, Bijol V, Das K. Granulomatous myocarditis arising from intravesical Bacillus Calmette-Gu\u00e9rin therapy leading to death diagnosed by postmortem examination: a case report. J Med Case Rep. 2024;18(1):12.","DOI":"10.1186\/s13256-023-04310-4"},{"key":"1363_CR103","doi-asserted-by":"crossref","unstructured":"Welty NE, Gill SI. Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncology. 2022;4(5):563-78.","DOI":"10.1016\/j.jaccao.2022.11.006"},{"key":"1363_CR104","doi-asserted-by":"crossref","unstructured":"Holder PG, Lim SA, Huang CS, Sharma P, Dagdas YS, Bulutoglu B, et al. Engineering interferons and interleukins for cancer immunotherapy. Adv Drug Delivery Rev. 2022;182:114112.","DOI":"10.1016\/j.addr.2022.114112"},{"key":"1363_CR105","doi-asserted-by":"crossref","unstructured":"Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunology (Baltimore, Md : 1950). 2014;192(12):5451-8.","DOI":"10.4049\/jimmunol.1490019"},{"key":"1363_CR106","doi-asserted-by":"crossref","unstructured":"Waldmann TA. Cytokines in Cancer Immunotherapy. Cold Spring Harbor perspectives in biology. 2018;10(12).","DOI":"10.1101\/cshperspect.a028472"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01363-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01363-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01363-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:02:53Z","timestamp":1763647373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01363-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":106,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1363"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01363-z","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}